Background：To explore the application value of the urinary albumin-to-creatinine ratio (UACR) in the predictive of coronary artery (CA) abnormalities in Kawasaki disease (KD) during acute phase.

For patients with CKD and T2D, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either agent alone.

For patients with CKD and T2D, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either agent alone.